Basis: FMP quote price / unrounded diluted EPS from four consecutive issuer fiscal quarters. Source: stored company filings and market data; unavailable inputs remain N/A.
The P/E ratio is N/A as of 2026-10-06T14:47:06.090Z.
Calculation as of: 2026-10-06T14:47:06.090Z.
Quote observation: 2026-10-06T14:44:46.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: a63c12ce7055b0216585e16b4e08b2fd6453147ab6d4be874ec80e726ee32667
PE RATIO
N/A
Market Cap
$122.96M
PE Ratio
N/A
TTM Avg
1239.77
3Y Avg
1350.84
5Y Avg
1350.84
Market Cap
$136.65M
PE Ratio
N/A
TTM Avg
1879.79
3Y Avg
1257.96
5Y Avg
875.52
| NAME | MARKET CAP | PE RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Health Catalyst, Inc. (HCAT) | $129.68M | N/A | N/A | N/A | N/A |
| Organigram Global Inc. (OGI)vs › | $131.20M | 2.09 | 9.74 | 18.49 | 18.49 |
| Freenome, Inc. (FRNM)vs › | $132.66M | N/A | N/A | N/A | N/A |
| Entera Bio Ltd. (ENTX)vs › | $126.43M | N/A | 2.13 | 2.46 | 2.46 |
| LifeMD, Inc. (LFMD)vs › | $135.12M | N/A | 18.93 | 18.93 | 18.93 |
| Cibus, Inc. (CBUS)vs › | $122.89M | N/A | N/A | N/A | N/A |
| NRx Pharmaceuticals, Inc. (NRXP)vs › | $122.96M | N/A | 1239.77 | 1350.84 | 1350.84 |
| KORU Medical Systems, Inc. (KRMD)vs › | $136.65M | N/A | 1879.79 | 1257.96 | 875.52 |
| Fortress Biotech, Inc. (FBIOP)vs › | $137.77M | 6.52 | 6.25 | 6.25 | 6.25 |
| enGene Holdings Inc. (ENGN)vs › | $121.25M | N/A | N/A | N/A | N/A |
Trailing P/E
N/A
Forward P/E
N/A
Forward P/E is calculated using analyst consensus EPS estimates for the current or next fiscal year.
Calculation:
Current Price
$1.75
Forward EPS (Est.)
$-0.04
Forward P/E
N/A
Source: FMP Analyst Consensus Estimates. Forward EPS represents the average analyst estimate for the nearest fiscal year.
PE Ratio = Share Price / Diluted EPS (TTM)
The price-to-earnings ratio measures how much investors pay for each dollar of trailing earnings. A lower PE can indicate a cheaper valuation; a higher PE implies higher growth expectations.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
